SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

Γ

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] ABERCROMBIE GEORGE B					2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
				BCRX												10% Ov				
(Last) PO BOX	Last) (First) (Middle) 20 BOX 16069					3. Date of Earliest Transaction (Month/Day/Year) 06/12/2024								Officer below)	(give title		Other (s below)	pecify		
-					_ 4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)														<i>,</i>	led by One	e Report	ting Perso	n		
CHAPE		NC	27516		_									Form filed by More than One Reporting Person						
(City)		State)	(Zip)		Rule	Rule 10b5-1(c) Transaction Indication														
					Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Inst										n or written	plan that	is intended	l to		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) Date (Month/				2A. Deemed Execution Date, if any (Month/Day/Yea	Cod	Transaction Code (Instr.						5. Amou Securitie Beneficia Owned F Reported	s ally ollowing	6. Own Form: I (D) or I (I) (Inst	Direct ndirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Cod	e v	'	Amount		(A) or (D)	Price	Transact	Transaction(s) (Instr. 3 and 4)			(1150. 4)			
Common Stock 06/12				2/2024		A			6,820 ⁽¹⁾ A		\$ <mark>0</mark>	36	36,431		D					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security	2. Conversion		3A. Deeme Execution if any	Date,	4. Transaction Code (Instr.	ransaction of			6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amo of Securities Underlying					ount 8. Price of 9. Number Derivative derivative Security Securities			I0. Dwnership ⁼orm:	11. Nature of Indirect Beneficial		

Derivative Security (Instr. 3)		Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Da (Month/Day/Y		of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
	Automatic Stock Option Grant ⁽²⁾	\$6.3	06/12/2024		A		49,933		06/12/2025	06/12/2034	Common Stock	49,933	\$0	49,933	D		

Explanation of Responses:

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

<u>/s/ Alane P. Barnes, by power</u> of attorney

06/14/2024

** Signature of Reporting Person Da

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

n Date